Coherus Oncology, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 7, 2025 and accepted by EDGAR at Aug 7, 2025, 16:55 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $10.3m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $17.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $3.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $6.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $26.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $50.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $26.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-30 | $52.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$45.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$90.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $2.3m | us-gaap:InterestExpense |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $4.4m | us-gaap:InterestExpense |
| Net income | 3 months2025-04-01 to 2025-06-30 | $297.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | $241.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | $2.57 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | $2.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | $2.57 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | $2.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 116,077,710 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 115,968,352 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$72.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-06-30 | $216.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $380.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $439.5m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $263.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $319.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $119.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-25-010803. Last ingested by Listed: Oct 29, 2026, 08:11 ET. Listed shows no prices and gives no investment advice.